Item Number: TARDAK
Presentation A sterile aqueous suspension for injection of micronised delmadinone acetate. Delmadinone acetate is 8-chloro-17 a-hydroxypregna-1,4,6-triene-3,20-dione acetate. Each ml contains 10 mg delmadinone acetate. This product contains benzalkonium chloride 0.01% as a preservative. Uses Tardak is for use in male dogs and cats in the following indications: 1.The treatment of hypersexuality (including vagrancy). 2.The relief of prostatic hypertrophy whether benign, carcinomatous or when due to chronic inflammatory processes. (In cases of the latter, relief cannot be expected unless appropriate accompanying therapy, such as corticoids or antibiotics is also instituted.) 3.For the treatment of circum-anal tumours. 4.For the treatment of certain forms of aggressiveness, nervousness, epileptiform seizures and corticoid-resistant pruritus (developing into dermatoses and accompanied by alopecia). Dosage and administration Route: Intramuscular or subcutaneous injection. Dose levels should be individually selected, taking into consideration the weight of the animal and the severity of the condition to be treated. The following dosage recommendations may be taken as a guideline. Up to 10 kg 1.5–2.0 mg/kg body weight 10 to 20 kg 1.0–1.5 mg/kg body weight 20 kg and above 1.0 mg/kg body weight In most cases it is necessary to allow two to four days to elapse before the effect of the treatment is observed. Dogs not showing improvement within eight days should be treated a second time with at least the dose-level previously given. Animals showing a favourable response can be expected to require follow-up treatment after a three to four week period. Further treatment in `social indications' is recommended at the first sign of reappearance of the effectively controlled indication. Contra-indications, warnings, etc Owners should be clearly warned that an immediate effect cannot be expected following administration of Tardak. In most cases it is necessary to allow two to four days to elapse before the effect of treatment is observed. Tardak should not be used in dogs already receiving progestagens. Animals treated with Tardak at stud could show a transient reduction in fertility and libido. Transient side-effects of increased appetite, polydipsia and polyuria have occasionally been seen following administration of Tardak. Controlling food intake will prevent an increase in bodyweight. However, where these effects are excessive, therapy should cease. As some progestagen injections can cause local changes in the hair coat such as lightening of colour and/or hair loss, it is recommended that subcutaneous injections are given at an inconspicuous site, e.g. inner surface of the thigh. Tardak should be used with great care when animals are under treatment with other steroids. Pharmaceutical precautions Shake the container before use. Do not store above 25°C. Protect from light. Following withdrawal of the first dose, use the product within 28 days. Discard any unused material. Any unused product or waste material should be disposed of in accordance with national requirements. Keep out of the reach of children. For animal treatment only. Legal category POM-V (previously POM). Packaging Quantities 10 ml vials. Marketing authorisation number Vm 00057/4156.
There have been no questions/answers for this product so far.
There have been no reviews for this product.